Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Pancreatic Neoplasms 2Glioblastoma 2Triple Negative Breast Neoplasms 1Gliosarcoma 1Glioma 1Breast Neoplasms 1Astrocytoma 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Magnetic Resonance Spectroscopy 13Temozolomide 12Specimen Handling 8X-Rays 7Biopsy 7Nuclear Medicine Department, Hospital 6Radiation 5Phantoms, Imaging 5trametinib 4erdafitinib 4dabrafenib 4ulixertinib 3larotrectinib 3Radiotherapy 3tipifarnib 2selpercatinib 2palbociclib 2olutasidenib 2olaparib 2ivosidenib 2ensartinib 2binimetinib 2Nivolumab 2D2C7-(scdsFv)-PE38KDEL 2vorasidenib 1veliparib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1tazemetostat 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × veliparib × 30 days × Clear all
NCT03581292 2026-05-27

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

National Cancer Institute (NCI)

Phase 2 Active not recruiting
38 enrolled 13 charts
CNS

Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡